Marcos de Lima, MD
Showing of 4 results
First-in-the-nation trial will use technology to target oportunistic infections - Innovations in Cancer | Wnter 2017
Innovations in Cancer - Summer 2016 - View Full PDF As a treatment for acute myeloid leukemia (AML), natural killer (NK) cells show encouraging potential. Because these cells are highly active in killing cancer, researchers have focused on...
Improving the Odds
Trial-focused SCT Program at UH Seidman Cancer Center looks to boost cure rates for hematologic malignancies Innovations in Cancer - Winter 2016 Download PDF Marcos de Lima, MD After stem cell transplant (SCT), cure rates for hematologic...
A Paradigm Shift for Improving Hematologic Malignancy Outcomes in Adults
Oncology - January 2016 Marcos de Lima, MD Stem Cell Transplant Director Marcos de Lima, MD, new to UH Seidman Cancer Center from M.D. Anderson Cancer Center, has shown that injecting combined human cord blood cells and mesenchymal stromal...